Market closed

Penumbra/$PEN

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Penumbra

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Ticker

$PEN

Sector

Health Care

Trading on

NYSE

Industry

Health Care Equipment & Supplies

Headquarters

Alameda, United States

Employees

4,200

Website

www.penumbrainc.com

Penumbra Metrics

BasicAdvanced

$9.5B

278.86 $0.89

0.54 -

Price and volume

Market cap

$9.5B

Beta

0.54

52-week high

$277.34

52-week low

$148.00

Average daily volume

355K

Financial strength

Current ratio

5.821

Quick ratio

3.049

Long term debt to equity

19.217

Total debt to equity

20.528

Interest coverage (TTM)

51.73%

Management effectiveness

Return on assets (TTM)

3.33%

Return on equity (TTM)

3.13%

Valuation

Price to earnings (TTM)

278.862

Price to revenue (TTM)

8.209

Price to book

8.58

Price to tangible book (TTM)

10.18

Price to free cash flow (TTM)

71.198

Growth

Revenue change (TTM)

16.96%

Earnings per share change (TTM)

-15.96%

3-year revenue growth (CAGR)

17.88%

3-year earnings per share growth (CAGR)

-0.53%

What the Analysts think about Penumbra

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Penumbra stock.

Penumbra Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Penumbra Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Penumbra News

AllArticlesVideos

Penumbra Is Poised For Growth As Blood Clot Awareness Rises: Analyst

Benzinga·4 weeks ago

Penumbra, Inc. (PEN) Q3 2024 Earnings Call Transcript

Seeking Alpha·3 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PEN

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Penumbra stock?

Penumbra (PEN) has a market cap of $9.5B as of January 15, 2025.

What is the P/E ratio for Penumbra stock?

The price to earnings (P/E) ratio for Penumbra (PEN) stock is 278.86 as of January 15, 2025.

Does Penumbra stock pay dividends?

No, Penumbra (PEN) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Penumbra dividend payment date?

Penumbra (PEN) stock does not pay dividends to its shareholders.

What is the beta indicator for Penumbra?

Penumbra (PEN) has a beta rating of 0.54. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.